이 페이지의 번역은 실험적이며 개발 중입니다. 여러분의 환영합니다!

MiMedx Group 관리

관리 기준 확인 1/4

MiMedx Group's CEO는 Joe Capper, Jan2023 에 임명되었습니다 의 임기는 1.42 년입니다. 총 연간 보상은 $ 20.76M, 3.3% 로 구성됩니다. 3.3% 급여 및 96.7% 보너스(회사 주식 및 옵션 포함). 는 $ 691.01K 가치에 해당하는 회사 주식의 0.068% 직접 소유합니다. 691.01K. 경영진과 이사회의 평균 재임 기간은 각각 1.8 년과 3.9 년입니다.

주요 정보

Joe Capper

최고 경영자

US$20.8m

총 보상

CEO 급여 비율	3.3%
CEO 임기	1.4yrs
CEO 소유권	0.07%
경영진 평균 재임 기간	1.8yrs
이사회 평균 재임 기간	3.9yrs

최근 관리 업데이트

Recent updates

MiMedx Group, Inc.'s (NASDAQ:MDXG) Shares Bounce 27% But Its Business Still Trails The Industry

May 21

We Think MiMedx Group (NASDAQ:MDXG) Can Stay On Top Of Its Debt

May 14

Improved Revenues Required Before MiMedx Group, Inc. (NASDAQ:MDXG) Shares Find Their Feet

Mar 27

We Think MiMedx Group (NASDAQ:MDXG) Can Stay On Top Of Its Debt

Jan 05

MiMedx Group, Inc. (NASDAQ:MDXG) Stock Catapults 27% Though Its Price And Business Still Lag The Industry

Dec 18

CEO 보상 분석

Joe Capper 의 보수는 MiMedx Group 의 수익과 비교하여 어떻게 변경되었나요?
날짜	총 보상	급여	회사 수익
Mar 31 2024	n/a	n/a	US$68m
Dec 31 2023	US$21m	US$678k	US$56m

보상 대 시장: Joe 의 총 보상 ($USD 20.76M )은 US 시장( $USD 3.43M ).

보상과 수익: Joe 의 보상을 회사 성과와 비교하기에는 데이터가 부족합니다.

CEO

Joe Capper (60 yo)

1.4yrs

테뉴어

US$20,756,346

보상

Mr. Joseph H. Capper, also known as Joe, is an Independent Director at Anika Therapeutics, Inc since May 28, 2024. He serves as Chief Executive Officer and Director of MiMedx Group, Inc. since January 30,...

리더십 팀

이름	위치	테뉴어	보상	소유권
Joseph Capper	CEO & Director	1.4yrs	US$20.76m	0.068% $ 680.0k
Douglas Rice	Chief Financial Officer	less than a year	US$2.75m	0.0034% $ 34.0k
William Hulse	General Counsel & Chief Administrative Officer	4.5yrs	US$1.91m	0.17% $ 1.7m
Scott Turner	Senior Vice President of Operations & Procurement	1.2yrs	US$619.46k	0% $ 0
Matthew Notarianni	Head of Investor Relations	1.7yrs	데이터 없음	데이터 없음
Mark Graves	Senior VP & Chief Compliance Officer	1.2yrs	데이터 없음	데이터 없음
Hilary Dixon	Vice President of Investor Relations & Corporate Strategic Communications	no data	데이터 없음	데이터 없음
Kate Surdez	Chief Human Resources Officer	1.9yrs	데이터 없음	데이터 없음
David Mason	Chief Medical Officer	5.5yrs	데이터 없음	데이터 없음
Robert Stein	President of Regenerative Medicine & Biologics Innovation	3.8yrs	US$1.74m	데이터 없음
Rebeccah J. Brown	Vice President of Global Regulatory Affairs	11.2yrs	US$198.47k	데이터 없음

1.8yrs

평균 재임 기간

58yo

평균 연령

경험이 풍부한 관리: MDXG 의 관리팀은 경험 (평균 재직 기간 1.8 년)으로 간주되지 않으므로 새로운 팀을 추천합니다.

이사회 구성원

이름	위치	테뉴어	보상	소유권
Joseph Capper	CEO & Director	1.4yrs	US$20.76m	0.068% $ 680.0k
Martin Sutter	Independent Preferred Director	3.9yrs	데이터 없음	0.00034% $ 3.4k
James Bierman	Independent Director	5yrs	US$278.43k	0.11% $ 1.1m
William Hawkins	Independent Preferred Director	3.9yrs	US$264.50k	0.10% $ 1.0m
James Andrews	Member of Medical Advisory Board	no data	데이터 없음	데이터 없음
Thomas Zdeblick	Member of Medical Advisory Board	no data	데이터 없음	데이터 없음
Cato Laurencin	Independent Director	3.6yrs	US$282.14k	0.088% $ 884.9k
K. Newton	Independent Director	5yrs	US$1.35m	0.24% $ 2.5m
Robert Guldberg	Member of Regenerative Medicine Scientific Advisory Board	no data	데이터 없음	데이터 없음
Glenn Gaston	Member of Medical Advisory Board	no data	데이터 없음	데이터 없음
Kris Alden	Member of Regenerative Medicine Scientific Advisory Board	1.9yrs	데이터 없음	데이터 없음
M. Behrens Wilsey	Independent Chairman of the Board	5yrs	US$340.50k	데이터 없음

3.9yrs

평균 재임 기간

69.5yo

평균 연령

경험이 풍부한 이사회: MDXG 의 이사회는 경험(평균 재직 기간 3.9 년)으로 간주됩니다.

MiMedx Group 관리

관리 기준 확인 1/4

주요 정보

최근 관리 업데이트

MiMedx Group, Inc., Annual General Meeting, Jun 05, 2024

Insider recently sold US$162k worth of stock

MiMedx Group, Inc. Announces Appointment of New Independent Directors

Insider recently sold US$250k worth of stock

Mimedx Group, Inc. Announces Retirement of Mr. William Phelan as Chief Accounting Officer

MiMedx Group, Inc. Announces Chief Financial Officer Changes

Recent updates

MiMedx Group, Inc.'s (NASDAQ:MDXG) Shares Bounce 27% But Its Business Still Trails The Industry

We Think MiMedx Group (NASDAQ:MDXG) Can Stay On Top Of Its Debt

Investor sentiment improves as stock rises 18%

First quarter 2024 earnings: EPS and revenues exceed analyst expectations

MiMedx Group, Inc., Annual General Meeting, Jun 05, 2024

MiMedx Group, Inc. to Report Q1, 2024 Results on Apr 30, 2024

MiMedx Group, Inc. Provides Update on AXIOFILL Request for Designation (RFD) from FDA

Improved Revenues Required Before MiMedx Group, Inc. (NASDAQ:MDXG) Shares Find Their Feet

Insider recently sold US$162k worth of stock

Mimedx Introduces E-Commerce and Account Management Platform

MiMedx Group, Inc. Announces Appointment of New Independent Directors

Full year 2023 earnings: EPS exceeds analyst expectations

New minor risk - Insider selling

Insider recently sold US$250k worth of stock

MiMedx Group, Inc. to Report Q4, 2023 Results on Feb 28, 2024

We Think MiMedx Group (NASDAQ:MDXG) Can Stay On Top Of Its Debt

Forecast breakeven date pushed back to 2024

MiMedx Group, Inc. (NASDAQ:MDXG) Stock Catapults 27% Though Its Price And Business Still Lag The Industry

Third quarter 2023 earnings: EPS and revenues exceed analyst expectations

Forecast breakeven date pushed back to 2024

MiMedx Group, Inc. to Report Q3, 2023 Results on Oct 30, 2023

Mimedx Group, Inc. Announces Launch of Epieffect

Mimedx Group, Inc. Announces Retirement of Mr. William Phelan as Chief Accounting Officer

Is MiMedx Group (NASDAQ:MDXG) Using Debt In A Risky Way?

MiMedx Group, Inc. Provides Earnings Guidance for the Fiscal Year 2023

Second quarter 2023 earnings released: EPS: US$0.01 (vs US$0.11 loss in 2Q 2022)

Price target increased by 8.0% to US$10.17

Forecast breakeven date moved forward to 2023

MiMedx Group, Inc. Announces Chief Financial Officer Changes

Consensus EPS estimates upgraded to US$0.10 loss

Price target decreased by 9.3% to US$9.29

Insider recently sold US$84k worth of stock

Insider notifies of intention to sell stock

MiMedx Group, Inc., Annual General Meeting, Jun 13, 2023

Insider recently sold US$276k worth of stock

Insider notifies of intention to sell stock

First quarter 2023 earnings: EPS and revenues exceed analyst expectations

Does MiMedx Group (NASDAQ:MDXG) Have A Healthy Balance Sheet?

Insider notifies of intention to sell stock

Chief Financial Officer recently sold US$85k worth of stock

Chief Financial Officer notifies of intention to sell stock

MiMedx Group, Inc. Announces Chief Executive Officer Changes

MiMedx Group, Inc. to Report Q4, 2022 Results on Mar 01, 2023

MiMedx Group, Inc. Appoints Ricci S. Whitlow as Chief Operating Officer

Health Check: How Prudently Does MiMedx Group (NASDAQ:MDXG) Use Debt?

MiMedx Group, Inc. Announces the Resignation of Rohit Kashyap as President, Wound Care and Surgical, Effective January 3, 2023

Price target decreased to US$10.25

High number of new directors

Third quarter 2022 earnings: EPS and revenues exceed analyst expectations

MiMedx Group, Inc. Provides Net Sales Guidance for the Fourth Quarter and Full Year 2022

MiMedx Group, Inc. to Report Q3, 2022 Results on Nov 02, 2022

Price target decreased to US$10.25

Mimedx Group, Inc. Announces Management Changes

High number of new directors

MiMedx Group, Inc. Announces Launch of AXIOFILL

MiMedx Group, Inc. Announces Launch of AMNIOEFFECT™

Insider recently sold US$94k worth of stock

MIMEDX EPIFIX® Receives Reimbursement Approval in Japan

MiMedx gets Japanese reimbursement approval for its tissue allograft EPIFIX

Consensus EPS estimates fall by 12%

MiMedx Group, Inc. Provides Sales Guidance for the Year Ending December 31, 2022

MiMedx Group expects AWC full-year sales in low end of 11%-14% growth range

Insider recently sold US$71k worth of stock

Consensus forecasts updated

Second quarter 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

MiMedx Group, Inc. Reaffirms Revenue Guidance for 2022

High number of new directors

MiMedx Group, Inc. Forms Regenerative Medicine Scientific Advisory Board Comprised of Renowned Industry and Academic Experts

MiMedx Group, Inc. to Report Q2, 2022 Results on Aug 02, 2022